Nephrogen: Curative Gene Therapies for Kidney Diseases
Revolutionizing Kidney Disease Treatment
Nephrogen is a pioneering seed-stage biotech company dedicated to developing curative gene therapies for life-threatening kidney diseases. Our primary focus is on autosomal dominant polycystic kidney disease (ADPKD), a condition affecting 600,000 Americans with no current cure or effective treatment.
Key Features
- Curative Gene Therapies: Utilizing CRISPR-Cas genome editing and advanced nucleic delivery systems like adeno-associated viruses (AAVs).
- Non-Invasive Delivery: Innovative methods for local gene therapy delivery to the kidney.
- Precision Therapy: Engineered AAV viruses with 100x better efficiency in targeting the kidney.
- Personalized Approach: Targeting unique gene mutations in PKD1, the gene responsible for ADPKD.
- Rapid Drug Discovery: Leveraging computer vision and high-throughput screening (HTS) for discovering new small molecule drugs.
Use Cases
- ADPKD Treatment: Providing a potential cure for autosomal dominant polycystic kidney disease.
- Other Cystic Kidney Diseases: Expanding research and treatment options for conditions like nephronophthisis.
Pricing
Nephrogen is currently in the seed stage, focusing on research and development. Pricing details for our therapies will be provided as we advance through clinical trials and regulatory approvals.
Teams
Leadership
- Demetri Maxim: Founder and CEO, with extensive research experience in kidney diseases.
- Vivek Bhalla, MD: Chief Medical Advisor, Associate Professor of Medicine (Nephrology) at Stanford University.
Research Team
- Maggie Thompson: Research Associate, specializing in biomolecular science and public health.
- Najani Johnson: Computational Biology Intern, focusing on drug discovery and machine learning.
- Miriam Rivera Moreno: Emerging Scientist Fellow, with a background in bioengineering and synthetic biology.
Advisors
- George Church, PhD: Professor of Genetics at Harvard Medical School.
- Avnesh Thakor, MD, PhD: Associate Professor of Radiology at Stanford University.
- Mark Kay, MD, PhD: Professor of Genetics at Stanford University.
- Terry Watnick, MD: Director of the Polycystic Kidney Disease Research Resource Consortium.
- Vishal Patel, MD: Professor of Medicine/Nephrology at UT Southwestern Medical Center.
- Ron Perrone, MD: Professor of Nephrology at Tufts University School of Medicine.
- Shelley Amster: Founder of ShelleyCO, business development consultant.
- Jan Liphardt, PhD: Associate Professor of Bioengineering at Stanford University.
Nephrogen is committed to transforming the landscape of kidney disease treatment through innovative gene therapies and a dedicated team of experts.
